Under leadership of its fourth Center Director, John L. Cleveland, PhD, the singular mission of Moffitt Cancer
Center (“Moffitt”), established in state statute only 30 years ago, is “to contribute to the prevention and cure of
cancer.” Fully informed by cancer needs in our community and catchment area; guided by highly effective, driven
and synergistic senior leadership and a rigorous research strategic plan; supported by tremendous institutional
funding; and cultivated by its five research Programs that span the basic, population, data, and clinical sciences;
Moffitt fosters exceptional cancer research that spans discovery to translation to the clinic and to the community.
Moffitt serves a 15-county catchment area of West Central Florida comprised of diverse sociodemographic
groups and vulnerable populations, including Blacks, Hispanics (particularly of Puerto Rican descent), rural
residents, persons living with HIV, and the elderly. Key catchment area cancers at higher incidence than the
state and nation include lung, melanoma, ovarian and HPV-related cancers (oropharynx, cervix). Community-
driven priorities are cancer prevention and screening, access to care, clinical trials, and vulnerable populations.
Moffitt’s 183 Members are organized into five highly collaborative research Programs – Cancer Biology &
Evolution; Cancer Epidemiology; Health Outcomes & Behavior; Immuno-Oncology; and Molecular Medicine –
whose research is supported by four Centers of Excellence focused on catchment area needs. Members have
produced exceptional science, supported by 14 Shared Resources (2 developmental), more than $2M in annual
institutional pilot funds, and exceptional central administration. Peer-reviewed grants have increased 32% and
funding has risen to $36.0M, including $18.1M from NCI (excluding CCSG and $2.4M training grants). Members
now hold 68 MPI awards (53 peer-reviewed). 3,279 articles were published, including 543 in journals with an
impact factor > 10. Publication rates are 24.2%, 18.7%, and 91.2% for intra-programmatic, inter-programmatic,
and inter-Center collaborations, respectively. 123 INDs and 184 patents were filed, and 15,309 patients (16,321
including affiliates) were accrued to interventional trials; 5,471 to treatment trials (5,716 including affiliates).
Guided by a new Research & Education Training Office, Moffitt educated more than 5,700 students, trainees,
and faculty over the award period, impacting all five Programs and clinical activities. Moffitt has 15 peer-review
training grants (T32, R25, F and K) and two NCI-funded minority-focused inter-institutional partnerships.
Importantly, Moffitt’s research has provided paradigm shifts in our understanding of the cancer ecosystem, has
discovered and advanced new means to prevent, treat and even cure some forms of cancer, and has led to
changes in clinical practice and national health policy. Over the next cycle Moffitt research and clinical impact
will be accelerated by investments focused on: 1) our catchment area; 2) health disparities; 3) immuno-oncology;
4) metabolism; 5) data science; and 6) cancer care, delivery, and implementation science. These efforts will
support Moffitt’s remarkable growth trajectory for decades to come and its mission to reduce the cancer burden.